DK3043838T3 - Belægning af en vaskulær endoprotese - Google Patents
Belægning af en vaskulær endoprotese Download PDFInfo
- Publication number
- DK3043838T3 DK3043838T3 DK14784004.5T DK14784004T DK3043838T3 DK 3043838 T3 DK3043838 T3 DK 3043838T3 DK 14784004 T DK14784004 T DK 14784004T DK 3043838 T3 DK3043838 T3 DK 3043838T3
- Authority
- DK
- Denmark
- Prior art keywords
- vascular endoprosthesis
- active substance
- vascular
- polysaccharide
- endoprosthesis
- Prior art date
Links
- 230000002792 vascular Effects 0.000 title claims description 99
- 238000000576 coating method Methods 0.000 title claims description 23
- 239000011248 coating agent Substances 0.000 title claims description 22
- 239000013543 active substance Substances 0.000 claims description 94
- 150000004676 glycans Chemical class 0.000 claims description 44
- 229920001282 polysaccharide Polymers 0.000 claims description 44
- 239000005017 polysaccharide Substances 0.000 claims description 44
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 38
- 238000000034 method Methods 0.000 claims description 29
- 238000009736 wetting Methods 0.000 claims description 21
- 239000007788 liquid Substances 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 239000002904 solvent Substances 0.000 claims description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- 229930012538 Paclitaxel Natural products 0.000 claims description 10
- 229960001592 paclitaxel Drugs 0.000 claims description 10
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 10
- 229920002307 Dextran Polymers 0.000 claims description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 8
- 230000002209 hydrophobic effect Effects 0.000 claims description 6
- 150000002576 ketones Chemical class 0.000 claims description 6
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 5
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 5
- 229960002930 sirolimus Drugs 0.000 claims description 5
- 238000005096 rolling process Methods 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 229920001971 elastomer Polymers 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 239000003270 steroid hormone Substances 0.000 claims description 3
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 2
- 239000003246 corticosteroid Substances 0.000 claims description 2
- 229960001334 corticosteroids Drugs 0.000 claims description 2
- MDCUNMLZLNGCQA-HWOAGHQOSA-N elafin Chemical class N([C@H](C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H]1C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H]2CSSC[C@H]3C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CSSC[C@H]4C(=O)N5CCC[C@H]5C(=O)NCC(=O)N[C@H](C(N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]5N(CCC5)C(=O)[C@H]5N(CCC5)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H](C)NC2=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N4)C(=O)N[C@@H](CSSC1)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N3)=O)[C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(O)=O)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)C(C)C)C(C)C)C(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)N MDCUNMLZLNGCQA-HWOAGHQOSA-N 0.000 claims description 2
- 229960001967 tacrolimus Drugs 0.000 claims description 2
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims description 2
- 229960001727 tretinoin Drugs 0.000 claims description 2
- 102000016978 Orphan receptors Human genes 0.000 claims 1
- 108070000031 Orphan receptors Proteins 0.000 claims 1
- 239000000018 receptor agonist Substances 0.000 claims 1
- 229940044601 receptor agonist Drugs 0.000 claims 1
- 239000000758 substrate Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 description 26
- 230000000694 effects Effects 0.000 description 8
- 239000000203 mixture Substances 0.000 description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 150000001298 alcohols Chemical class 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 238000005507 spraying Methods 0.000 description 3
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 125000003158 alcohol group Chemical group 0.000 description 2
- 238000002399 angioplasty Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 208000037803 restenosis Diseases 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 238000009827 uniform distribution Methods 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 102000002149 Elafin Human genes 0.000 description 1
- 108010015972 Elafin Proteins 0.000 description 1
- 241000192132 Leuconostoc Species 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000002965 anti-thrombogenic effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000003130 blood coagulation factor inhibitor Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229940119744 dextran 40 Drugs 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000806 elastomer Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 238000005530 etching Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000005660 hydrophilic surface Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 230000009707 neogenesis Effects 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000003058 plasma substitute Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 230000020971 positive regulation of blood coagulation Effects 0.000 description 1
- 238000007788 roughening Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 229910001285 shape-memory alloy Inorganic materials 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 239000010887 waste solvent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/34—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D—PROCESSES FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D1/00—Processes for applying liquids or other fluent materials
- B05D1/002—Processes for applying liquids or other fluent materials the substrate being rotated
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
- C09D105/00—Coating compositions based on polysaccharides or on their derivatives, not provided for in groups C09D101/00 or C09D103/00
- C09D105/02—Dextran; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/606—Coatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/606—Coatings
- A61L2300/608—Coatings having two or more layers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2420/00—Materials or methods for coatings medical devices
- A61L2420/02—Methods for coating medical devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2420/00—Materials or methods for coatings medical devices
- A61L2420/08—Coatings comprising two or more layers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Organic Chemistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Surgery (AREA)
- Materials Engineering (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Prostheses (AREA)
- Media Introduction/Drainage Providing Device (AREA)
Claims (15)
1. Fremgangsmåde til belægning afen vaskulær endoprotese, hvilken fremgangsmåde omfatter følgende trin: a) i det mindste en delvis befugtning af ydersiden af den vaskulære endoprotese med en første opløsning af en aktiv substans; b) bevægelse af den vaskulære endoprotese med en rotationsbevægelse omkring den langsgående akse for den vaskulære endoprotese; c) påføring af en radialt virkende mekanisk kraft på ydersiden af den vaskulære endoprotese.
2. Fremgangsmåde ifølge krav 1, kendetegnet ved, at den radialt virkende mekaniske kraft påføres på ydersiden af den vaskulære endoprotese ved at rulle den vaskulære endoprotese over en overflade under udøvelse af et tryk.
3. Fremgangsmåde ifølge krav 2, kendetegnet ved, at overfladen er en elastomer overflade, især en gummioverflade.
4. Fremgangsmåde ifølge ethvert af kravene 1 til 3, kendetegnet ved, at den vaskulære endoprotese bevæges i en rotationsbevægelse omkring den langsgående akse med en rotationshastighed på i det mindste 1000 omdr/min., fortrinsvis i det mindste 2000 omdr/min., især fortrinsvis i det mindste 5000 omdr/min.
5. Fremgangsmåde ifølge ethvert af kravene 1 til 4, kendetegnet ved, at den første opløsning omfatter chloroform eller dichlormethan som opløsningsmiddel.
6. Fremgangsmåde ifølge ethvert af kravene 1 til 5, kendetegnet ved, at den anvendte aktive substans er valgt fra gruppen bestående af: tretinoin, orphanreceptoragonister, elafinderivater, corticosteroider, steroidhormoner, paclitaxel, rapamycin, sirolimus, tacrolimus, hydrofobe proteiner og/eller celleproliferationsændrende substanser.
7. Fremgangsmåde ifølge ethvert af kravene 1 til 6, omfattende som et yderligere trin: d) befugtning af de områder af ydersiden af den vaskulære endoprotese, som er befugtet med den første opløsning af den aktive substans, med en væske omfattende vand og/eller i det mindste én alkohol; hvor trin d) udøves efter trinnene (a) til (c).
8. Fremgangsmåde ifølge krav 7, kendetegnet ved, at væsken, som omfatter vand og/eller i det mindste én alkohol, omfatter en alkohol og/eller en keton.
9. Fremgangsmåde ifølge krav 8, kendetegnet ved, at koncentrationen af alkoholen og/eller ketonen i væsken udgør 10 op til 70% (v/v), fortrinsvis 20 til 40% (v/v).
10. Fremgangsmåde ifølge ethvert af kravene 7 til 9, kendetegnet ved, at væsken omfatter ethanol, methanol, acetone og/eller isopropanol.
11. Fremgangsmåde ifølge ethvert af kravene 1 til 10, omfattende som et yderligere trin: e) befugtning af de områder af ydersiden af den vaskulære endoprotese, som er befugtede med den første opløsning og, hvis nogen, med væsken omfattende vand og/eller i det mindste én alkohol, med en yderligere opløsning, som omfatter et polysaccharid; hvor trin (e) udøves efter trinnene (a) til (c) eller (a) til (d).
12. Fremgangsmåde ifølge krav 11, kendetegnet ved, at middelmolekylmassen for polysaccharidet udgør 10.000 op til 100.000.000 Da, fortrinsvis 20.000 op til 80.000 Da.
13. Fremgangsmåde ifølge krav 11 eller 12, kendetegnet ved, at polysaccharidet er en dextran.
14. Vaskulær endoprotese, hvis yderside i det mindste delvis har en belægning med paclitaxel, som kan tilvejebringes ved hjælp af en fremgangsmåde ifølge ethvert af kravene 6 til 13.
15. Vaskulær endoprotese, hvis yderside i det mindste delvis har en belægning med en aktiv substans, som kan tilvejebringes ved hjælp af en fremgangsmåde ifølge ethvert af kravene 11 til 13, kendetegnet ved, at den aktive substrans er dækket af poly-saccharidet.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE201310014821 DE102013014821A1 (de) | 2013-09-10 | 2013-09-10 | Gefäßendoprothesenbeschichtung |
| PCT/EP2014/069030 WO2015036343A1 (de) | 2013-09-10 | 2014-09-08 | GEFÄßENDOPROTHESENBESCHICHTUNG |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3043838T3 true DK3043838T3 (da) | 2018-09-17 |
Family
ID=51703130
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14784004.5T DK3043838T3 (da) | 2013-09-10 | 2014-09-08 | Belægning af en vaskulær endoprotese |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US9808559B2 (da) |
| EP (1) | EP3043838B1 (da) |
| JP (2) | JP6551802B2 (da) |
| DE (1) | DE102013014821A1 (da) |
| DK (1) | DK3043838T3 (da) |
| ES (1) | ES2686138T3 (da) |
| PL (1) | PL3043838T3 (da) |
| WO (1) | WO2015036343A1 (da) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102014014771A1 (de) * | 2014-10-10 | 2016-04-14 | Alexander Rübben | Gefäßendoprothesenbeschichtung |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5464650A (en) * | 1993-04-26 | 1995-11-07 | Medtronic, Inc. | Intravascular stent and method |
| CA2353606A1 (en) * | 1998-12-03 | 2000-06-08 | Boston Scientific Limited | Stent having drug crystals thereon |
| US7201940B1 (en) | 2001-06-12 | 2007-04-10 | Advanced Cardiovascular Systems, Inc. | Method and apparatus for thermal spray processing of medical devices |
| US7105198B2 (en) * | 2002-01-14 | 2006-09-12 | Medtronic Vascular, Inc. | Method for coating stent |
| US7858143B2 (en) * | 2002-03-15 | 2010-12-28 | Abbott Cardiovascular System Inc. | Apparatus and method for coating stents |
| US6971813B2 (en) * | 2002-09-27 | 2005-12-06 | Labcoat, Ltd. | Contact coating of prostheses |
| US8337937B2 (en) * | 2002-09-30 | 2012-12-25 | Abbott Cardiovascular Systems Inc. | Stent spin coating method |
| US7404979B1 (en) * | 2002-09-30 | 2008-07-29 | Advanced Cardiovascular Systems Inc. | Spin coating apparatus and a method for coating implantable devices |
| US8281737B2 (en) | 2003-03-10 | 2012-10-09 | Boston Scientific Scimed, Inc. | Coated medical device and method for manufacturing the same |
| US7867547B2 (en) * | 2005-12-19 | 2011-01-11 | Advanced Cardiovascular Systems, Inc. | Selectively coating luminal surfaces of stents |
| US7919108B2 (en) * | 2006-03-10 | 2011-04-05 | Cook Incorporated | Taxane coatings for implantable medical devices |
| DE102007004589A1 (de) * | 2007-01-30 | 2008-07-31 | Orlowski, Michael, Dr. | Bioresorbierbarer Metallstent mit kontrollierter Resorption |
| SG183035A1 (en) * | 2007-04-17 | 2012-08-30 | Micell Technologies Inc | Stents having biodegradable layers |
| LT2252340T (lt) | 2007-11-06 | 2016-11-25 | Alexander Rübben | Bioaktyvaus paviršiaus ant endoprotezo arba ant balioninio kateterio baliono gamybos būdas |
| EP2268332B1 (de) * | 2008-04-09 | 2019-01-16 | Aachen Scientific International PTE. LTD. | Verfahren zur erzeugung einer bioaktiven oberfläche auf einer endoprothese oder auf dem ballon eines ballonkatheters |
| IT1394522B1 (it) * | 2009-01-09 | 2012-07-05 | Invatec Technology Ct Gmbh | Dispositivo medicale con rilascio di farmaco |
| WO2010086863A2 (en) * | 2009-02-02 | 2010-08-05 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Crystalline drug-containing coatings |
| WO2010129328A2 (en) * | 2009-04-28 | 2010-11-11 | Surmodics, Inc. | Devices and methods for delivery of bioactive agents |
| DK2646066T3 (da) * | 2010-12-04 | 2018-06-25 | Aachen Scient International Pte Ltd | Belægning og belægningsfremgangsmåde for ballonen på et ballonkateter samt ballonkateter med belagt ballon |
-
2013
- 2013-09-10 DE DE201310014821 patent/DE102013014821A1/de not_active Withdrawn
-
2014
- 2014-09-08 ES ES14784004.5T patent/ES2686138T3/es active Active
- 2014-09-08 WO PCT/EP2014/069030 patent/WO2015036343A1/de not_active Ceased
- 2014-09-08 EP EP14784004.5A patent/EP3043838B1/de active Active
- 2014-09-08 US US15/021,183 patent/US9808559B2/en not_active Expired - Fee Related
- 2014-09-08 PL PL14784004T patent/PL3043838T3/pl unknown
- 2014-09-08 DK DK14784004.5T patent/DK3043838T3/da active
- 2014-09-08 JP JP2016541897A patent/JP6551802B2/ja not_active Expired - Fee Related
-
2017
- 2017-10-25 US US15/793,275 patent/US10994053B2/en not_active Expired - Fee Related
-
2019
- 2019-06-19 JP JP2019113481A patent/JP6820974B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015036343A1 (de) | 2015-03-19 |
| JP6551802B2 (ja) | 2019-07-31 |
| ES2686138T3 (es) | 2018-10-16 |
| EP3043838B1 (de) | 2018-06-06 |
| PL3043838T3 (pl) | 2019-01-31 |
| DE102013014821A1 (de) | 2015-03-12 |
| US10994053B2 (en) | 2021-05-04 |
| JP6820974B2 (ja) | 2021-01-27 |
| JP2019150678A (ja) | 2019-09-12 |
| US20160220733A1 (en) | 2016-08-04 |
| EP3043838A1 (de) | 2016-07-20 |
| JP2017500949A (ja) | 2017-01-12 |
| US20180043060A1 (en) | 2018-02-15 |
| US9808559B2 (en) | 2017-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4758474B2 (ja) | 血管ステントの表面全体のコーティング | |
| CN107823719B (zh) | 球囊表面涂层 | |
| JP5873076B2 (ja) | 有効成分を放出する無粒子コーティングを備えた医療品 | |
| CN101940802B (zh) | 药物缓释性支架 | |
| CN102573946A (zh) | 涂布导管球囊的组合物的用途和经涂布导管球囊 | |
| CN102458497A (zh) | 涂有虫胶和太平洋紫杉醇的导管球囊 | |
| KR20040050915A (ko) | 재협착증의 방지를 위한 스텐트의 코팅 | |
| EP2872192B1 (en) | Catheter with drug coating | |
| JP2017503606A (ja) | 医療器具のコーティング | |
| JP2015217260A (ja) | 医療機器 | |
| US10994053B2 (en) | Coating of a vascular endoprosthesis | |
| DK2854887T3 (da) | Belægning af ballonkatetere | |
| US20240366843A1 (en) | Polysaccharide coating | |
| US10213531B2 (en) | Coating of a vascular endoprosthesis | |
| CN115666669A (zh) | 微球药物涂覆的医疗装置和方法 | |
| JP3216992U (ja) | バルーンカテーテルのバルーン、および、バルーンカテーテル | |
| WO2014177221A1 (en) | Balloon surface coating | |
| CN105833355A (zh) | 带有活性物质涂层的医用产品和其制法 | |
| US20210346658A1 (en) | Active-substance coating for balloons of balloon catheters | |
| HK1207993B (en) | Balloon surface coating |